| dc.contributor.author | Baeten, Jared M. | |
| dc.contributor.author | Lingappa, Jairam | |
| dc.contributor.author | Beck, Ingrid | |
| dc.contributor.author | Frenkel, Lisa M. | |
| dc.contributor.author | Pepper, Gregory | |
| dc.contributor.author | Celum, Connie | |
| dc.contributor.author | Wald, Anna | |
| dc.contributor.author | Fife, Kenneth H. | |
| dc.contributor.author | Were, Edwin | |
| dc.contributor.author | Mugo, Nelly | |
| dc.contributor.author | Makhema, Joseph | |
| dc.contributor.author | Kiarie, James | |
| dc.date.accessioned | 2021-07-27T07:12:43Z | |
| dc.date.available | 2021-07-27T07:12:43Z | |
| dc.date.issued | 2011 | |
| dc.identifier.uri | https://doi.org/10.1093/infdis/jiq013 | |
| dc.identifier.uri | http://ir.mu.ac.ke:8080/jspui/handle/123456789/4935 | |
| dc.description.abstract | ecent in vitro studies suggest that acyclovir may directly inhibit HIV-1 replication and can select for a specific HIV-1 reverse transcriptase mutation (V75I) with concomitant loss of an anti-HIV-1 effect. We tested for HIV-1 genotypic resistance at reverse transcriptase codon 75 in plasma from 168 HIV-1–infected persons from Botswana, Kenya, Peru, and the United States taking daily acyclovir or valacyclovir for between 8 weeks and 24 months. No V75I cases were detected (95% confidence interval, 0%–2.2%). These prospective in vivo studies suggest that standard-dose acyclovir or valacyclovir does not select for HIV-1 resistance. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Oxford University Press | en_US |
| dc.subject | Herpes Simplex Virus | en_US |
| dc.subject | HIV-1 transmission | en_US |
| dc.title | Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons | en_US |
| dc.type | Article | en_US |
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||